Active Biotech

U.S. patent granted for biotech company's cancer project

Published in Medicine and Law Weekly, January 7th, 2005

The U.S. patent office has issued a notice of allowance for Active Biotech's TTS cancer project.

This patent is important for the TTS project and includes the possibility to use TTS as combination therapy. This patent is the first in a series of applications related to combination of TTS and other established pharmaceuticals for cancer treatment.

The patent is valid until 2018.

The TTS patent portfolio in the U.S. consist of six separate patent families. With this new patent approval, three families are granted in the U.S. and the remaining are under review.

In Europe, Active Biotech has seven patent families...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry